Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGAV | P06756 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30422053 | 1.00 | KMT2A (0.56) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL1921443 | 0.89 | KMT2A (0.50) | KMT2AEPHX2ENPP2 | |
| SCHEMBL30640436 | 0.89 | KMT2A (0.59) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL525564 | 0.89 | KMT2A (0.59) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL18688054 | 0.88 | EPHX2 (0.53) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL3177417 | 0.87 | KMT2A (0.62) | KMT2AEPHX2CASP3OPRD1FABP7 | |
| SCHEMBL119110 | 0.86 | KMT2A (0.53) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL29679265 | 0.86 | KMT2A (0.53) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL29618948 | 0.86 | KMT2A (0.53) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL19633130 | 0.85 | EPHX2 (0.66) | KMT2AEPHX2CASP3OPRD1FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| WO-2023137366-A2 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-04-13 | — | — | US | disclosed |
| US-11504441-B2 | Radiolabeled compounds targeting the prostate-specific membrane antigen | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-11-22 | — | — | US | disclosed |
| EP-3986872-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | Provincial Health Services Authority (CA) | 2022-04-27 | — | — | EP | disclosed |
| CN-114401947-A | Radiolabeled compounds targeting prostate specific membrane antigen | 省卫生服务机构 | 2022-04-26 | — | — | CN | disclosed |
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-11-04 | — | — | US | disclosed |
| US-20210198278-A1 | SECO MACROLIDE COMPOUNDS | SELVITA D.O.O. (HR) | 2021-07-01 | — | — | US | disclosed |
| WO-2020252598-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-12-24 | — | — | WO | disclosed |
| EP-2598157-B1 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION | SANOFI SA (FR) | 2016-10-12 | — | — | EP | disclosed |
| US-9073975-B2 | Cyclic peptides, their preparation and their use as inhibitors of the platelet adhesion | SANOFI (FR) | 2015-07-07 | — | — | US | disclosed |
| US-20140011734-A1 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION | SANOFI (FR) | 2014-01-09 | — | — | US | disclosed |
| EP-2598157-A1 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION | SANOFI (FR) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013709-A1 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011734-A1 | CYCLIC PEPTIDES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE PLATELET ADHESION | F12, F11, F13B | KMT2A 4818/4885EPHX2 2931/4885CASP3 1903/4885 |
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | KMT2A 1402/4885EPHX2 2303/4885CASP3 2161/4885 |
| US-20210198278-A1 | SECO MACROLIDE COMPOUNDS | SEC61B, SEC16A, SEC61A1 | KMT2A 4255/4885EPHX2 1144/4885CASP3 1238/4885 |
| US-11504441-B2 | Radiolabeled compounds targeting the prostate-specific membrane antigen | FOLH1, KLK3, PSMA3 | KMT2A 1402/4885EPHX2 2303/4885CASP3 2161/4885 |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | KMT2A 1402/4885EPHX2 2303/4885CASP3 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.